Angelo Pirozzi

Angelo Pirozzi

Auto-generated profile, based on publicly available information

Angelo Pirozzi

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
VZValentina Zanuso
Valentina Zanuso
APAngelo Pirozzi
Angelo Pirozzi
RBRita Balsano
Rita Balsano
TPTiziana Pressiani
Tiziana Pressiani
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
Hepatocellular carcinoma (HCC) is one of the most common leading causes of cancer death worldwide. As most patients are diagnosed with advanced disease, systemic therapy remains the backbone of treatment. In recent years, we have witnessed the transformation of advanced HCC treatment landscapes from single-agent targeted therapies to immunotherapy combinations, with atezolizumab plus bevacizumab becoming the new first-line standard of care with an increase in overall survival, progression-free survival, and objective response rate compared to sorafenib, and a positive impact on quality of life. Although the efficacy and safety of this combination have been confirmed regardless of ethnicity, age, and etiology, only a subgroup of patients seems to benefit the most from this treatment. Currently, predictive serum and tissue biomarkers to select patients who are most likely to respond to atezolizumab plus bevacizumab are lacking. Moreover, the optimal subsequent therapy for patients who progress on first-line atezolizumab plus bevacizumab remains unknown, clinical trials are ongoing, and real-world data are needed to determine the most effective treatment sequence. Importantly, careful evaluation of bleeding risk and preservation of adequate liver function are fundamental to improve patients’ prognosis, especially when subsequent treatments are administered.

1 January 2024 in Clinical Liver Disease
Verified
Journal Article
Closed access
VZValentina Zanuso
Valentina Zanuso
APAngelo Pirozzi
Angelo Pirozzi
GTGiulia Tesini
Giulia Tesini
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
Export